updated 9/9/2010 12:15:52 AM ET 2010-09-09T04:15:52

FAIRFIELD, Conn., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (OTCQB:CTTC) announced today the publication of the detailed results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTTC's Calmare® Pain Therapy Treatment. The article published in the Journal of Pain and Symptom Management (www.jpsmjournal.com), detailed the study led by principal investigator, Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center.

Calmare, which treats chronic neuropathic and oncologic pain, received FDA certification for sales in the U.S. in 2009. In June 2009, clinical investigators at the VCU Massey Cancer Center began the first U.S. independent clinical study, to specifically examine the ability of CTTC's Calmare pain therapy treatment to decrease pain associated with CIPN. 

"The Massey Cancer Center team, led by Dr. Smith, was the first independent group in the U.S. to conduct its own evidence-based study using the Calmare pain therapy device to treat CIPN in cancer patients. CIPN is a very debilitating side effect for some 30-40 percent of cancer patients, causing sharp pain in their hands and feet. CIPN affects cancer patients worldwide, including an estimated 4 million cancer patients in the U.S. Calmare pain therapy is the only highly effective treatment for CIPN without the harmful, adverse side effects of opioids," said Johnnie Johnson, Competitive Technologies' interim CEO.

"We are proud of the patient outcomes achieved with this breakthrough treatment in the clinical research study at VCU Massey Cancer Center, a National Cancer Institute-designated center that helps lead our nation's cancer research agenda," said Aris D. Despo, CTTC's Executive VP, Business Development. "We are excited about the investigators' success using Calmare in treating pain. This research confirms our approach to providing a solution to the needs of cancer patients and to improving palliative healthcare globally." 

Calmare is being used to treat international patients in Italy, India, Greece, Bangladesh, and U.S. patients at clinics in Utah, Texas, Massachusetts, New York, Virginia, Florida, Connecticut and Rhode Island.  In addition to treating pain associated with cancer and cancer treatments, Calmare Pain Therapy also successfully treats chronic neuropathic pain resulting from shingles, failed back surgery, phantom limb syndrome, sciatica, spinal stenosis and other maladies.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTTC is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTTC maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTTC's website: www.competitivetech.net .

The non-invasive Calmare® pain therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTTC's client, Professor Giuseppe Marineo. CTTC's partner, GEOMC Co. Ltd. of Seoul, Korea is manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales. For more information about Calmare Pain Therapy Treatment, visit www.CalmareTT.com .

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com